A phase II trial of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU, NSC 95466) in recurrent malignant brain tumors

Lynn G Feun, David J. Stewart, Milam E. Leavens, M. Andrew Burgess, Niramol Savaraj, Robert S. Benjamin, G. P. Bodey

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Twenty-nine with patients recurrent primary malignant brain tumors were treated with 1-(2-chlorethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU) at an initial dose of 110 Mg/M2 with subsequent doses determined by the degree of delayed toxicity. The interval between treatments was usually weeks. Eleven of 25 evaluable patients (44%) showed definite improvement and ten(40%) showed disease stability as determined by sequential CT scans and neurologic examination. The estimated median time to tumor progression for all 25 patients treated with PCNU was 28 weeks, 37 weeks for the responding patients but only 20 weeks for patients with stable disease. Toxicity consisted of delayed myelosuppression which was cumulative and occurred mainly with the platelets. Gastrointestinal toxicity occurred in a minority of the patients. PCNU has definite activity in primary malignant brain tumors which appears to be comparable to that reported for BCNU alone, but with less reported gastointestinal side effects. Further clinical trials in patients with primary malignant brain tumors are indicated.

Original languageEnglish
Pages (from-to)45-48
Number of pages4
JournalJournal of Neuro-Oncology
Volume1
Issue number1
DOIs
StatePublished - Mar 1 1983
Externally publishedYes

Fingerprint

Brain Neoplasms
Carmustine
Neurologic Examination
1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea
Blood Platelets
Clinical Trials
Neoplasms

Keywords

  • malignant gliomas
  • PCNU

ASJC Scopus subject areas

  • Neuroscience(all)
  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

A phase II trial of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU, NSC 95466) in recurrent malignant brain tumors. / Feun, Lynn G; Stewart, David J.; Leavens, Milam E.; Burgess, M. Andrew; Savaraj, Niramol; Benjamin, Robert S.; Bodey, G. P.

In: Journal of Neuro-Oncology, Vol. 1, No. 1, 01.03.1983, p. 45-48.

Research output: Contribution to journalArticle

Feun, Lynn G ; Stewart, David J. ; Leavens, Milam E. ; Burgess, M. Andrew ; Savaraj, Niramol ; Benjamin, Robert S. ; Bodey, G. P. / A phase II trial of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU, NSC 95466) in recurrent malignant brain tumors. In: Journal of Neuro-Oncology. 1983 ; Vol. 1, No. 1. pp. 45-48.
@article{0f1138e013e94230b31ed37b2a1a5702,
title = "A phase II trial of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU, NSC 95466) in recurrent malignant brain tumors",
abstract = "Twenty-nine with patients recurrent primary malignant brain tumors were treated with 1-(2-chlorethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU) at an initial dose of 110 Mg/M2 with subsequent doses determined by the degree of delayed toxicity. The interval between treatments was usually weeks. Eleven of 25 evaluable patients (44{\%}) showed definite improvement and ten(40{\%}) showed disease stability as determined by sequential CT scans and neurologic examination. The estimated median time to tumor progression for all 25 patients treated with PCNU was 28 weeks, 37 weeks for the responding patients but only 20 weeks for patients with stable disease. Toxicity consisted of delayed myelosuppression which was cumulative and occurred mainly with the platelets. Gastrointestinal toxicity occurred in a minority of the patients. PCNU has definite activity in primary malignant brain tumors which appears to be comparable to that reported for BCNU alone, but with less reported gastointestinal side effects. Further clinical trials in patients with primary malignant brain tumors are indicated.",
keywords = "malignant gliomas, PCNU",
author = "Feun, {Lynn G} and Stewart, {David J.} and Leavens, {Milam E.} and Burgess, {M. Andrew} and Niramol Savaraj and Benjamin, {Robert S.} and Bodey, {G. P.}",
year = "1983",
month = "3",
day = "1",
doi = "10.1007/BF00153640",
language = "English",
volume = "1",
pages = "45--48",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - A phase II trial of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU, NSC 95466) in recurrent malignant brain tumors

AU - Feun, Lynn G

AU - Stewart, David J.

AU - Leavens, Milam E.

AU - Burgess, M. Andrew

AU - Savaraj, Niramol

AU - Benjamin, Robert S.

AU - Bodey, G. P.

PY - 1983/3/1

Y1 - 1983/3/1

N2 - Twenty-nine with patients recurrent primary malignant brain tumors were treated with 1-(2-chlorethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU) at an initial dose of 110 Mg/M2 with subsequent doses determined by the degree of delayed toxicity. The interval between treatments was usually weeks. Eleven of 25 evaluable patients (44%) showed definite improvement and ten(40%) showed disease stability as determined by sequential CT scans and neurologic examination. The estimated median time to tumor progression for all 25 patients treated with PCNU was 28 weeks, 37 weeks for the responding patients but only 20 weeks for patients with stable disease. Toxicity consisted of delayed myelosuppression which was cumulative and occurred mainly with the platelets. Gastrointestinal toxicity occurred in a minority of the patients. PCNU has definite activity in primary malignant brain tumors which appears to be comparable to that reported for BCNU alone, but with less reported gastointestinal side effects. Further clinical trials in patients with primary malignant brain tumors are indicated.

AB - Twenty-nine with patients recurrent primary malignant brain tumors were treated with 1-(2-chlorethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU) at an initial dose of 110 Mg/M2 with subsequent doses determined by the degree of delayed toxicity. The interval between treatments was usually weeks. Eleven of 25 evaluable patients (44%) showed definite improvement and ten(40%) showed disease stability as determined by sequential CT scans and neurologic examination. The estimated median time to tumor progression for all 25 patients treated with PCNU was 28 weeks, 37 weeks for the responding patients but only 20 weeks for patients with stable disease. Toxicity consisted of delayed myelosuppression which was cumulative and occurred mainly with the platelets. Gastrointestinal toxicity occurred in a minority of the patients. PCNU has definite activity in primary malignant brain tumors which appears to be comparable to that reported for BCNU alone, but with less reported gastointestinal side effects. Further clinical trials in patients with primary malignant brain tumors are indicated.

KW - malignant gliomas

KW - PCNU

UR - http://www.scopus.com/inward/record.url?scp=0020961282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020961282&partnerID=8YFLogxK

U2 - 10.1007/BF00153640

DO - 10.1007/BF00153640

M3 - Article

C2 - 6678305

AN - SCOPUS:0020961282

VL - 1

SP - 45

EP - 48

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -